No internet connection — showing the saved version of the page.

BioNTech SE

DEEUR
← to the screener

BioNTech SE (US:BNTX) — Biotechnology: Biological Products (No Diagnostic Substances). Number of exchanges where the company shares trade: 3. On this page — price and chart, dividends, top holders and share count history.

About the company

Website
biontech.de
Investor relations
investors.biontech.de/de
Sector
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
Headquarters
MAINZ
Management
Ugur Sahin
IPO
2019-10-10
Shares outstanding
251.2 M as of 2026-03-27
Market cap
22.1 B EUR
Industry (SIC)
Biological Products, (No Diagnostic Substances)
Legal form
SGST
ISIN
US09075V1026
LEI
894500UZJ5LG1F8J1U58
P/E
loss
EPS
−6.83 USD
|
1.07
ROE
−8.0%
Payout ratio
0%
FCF
−476 M EUR
Debt
360 M EUR
negative FCF — not covered
Earnings, FCF and dividends paid — for the 12 months to 30.09.2026 (the company's latest report).
Net income
−1.14 B EUR year
For the financial year to 31.12.2025
Revenue2.87 B EUR
− Expenses4.27 B EUR
Gross profit2.23 B EUR
Net income−1.14 B EUR
History by year
RevenueExpensesLoss
31.12.2018: Revenue 128 M · Expenses 181 M · Operating profit −53.9 M · Net income −48.0 M31.12.2019: Revenue 109 M · Expenses 290 M · Operating profit −182 M · Net income −179 M31.12.2020: Revenue 482 M · Expenses 565 M · Operating profit −82.4 M · Net income 15.2 M31.12.2021: Revenue 19.0 B · Expenses 3.69 B · Operating profit 15.3 B · Net income 10.3 B31.12.2022: Revenue 17.3 B · Expenses 4.67 B · Operating profit 12.6 B · Net income 9.43 B31.12.2023: Revenue 3.82 B · Expenses 3.13 B · Operating profit 690 M · Net income 930 M31.12.2024: Revenue 2.75 B · Expenses 4.07 B · Operating profit −1.31 B · Net income −665 M31.12.2025: Revenue 2.87 B · Expenses 4.27 B · Operating profit −1.40 B · Net income −1.14 B
12.201812.2025
Green above orange is profit (revenue − expenses); red below zero is a loss.
NAV
71.44 EUR · P/NAV 1.00
Balance sheet date30.09.2026
Assets20.2 B EUR
− Liabilities2.46 B EUR
= NAV (equity of the company's shareholders)17.7 B EUR
− Goodwill376 M EUR
− Intangible assets1.20 B EUR
= Tangible NAV16.1 B EUR
Shares247 928 180
NAV per share71.44 EUR
Tangible NAV per share65.08 EUR
Share price (BNTX)81.3800 USD
P/NAV1.00
NAV history
Balance sheet dateNAVNAV per share
30.09.202617.7 B EUR71.44 EUR
30.06.202617.8 B EUR70.69 EUR
31.03.202618.7 B EUR73.94 EUR
31.12.202519.2 B EUR76.49 EUR
30.09.202518.5 B EUR76.84 EUR
31.12.202419.4 B EUR80.89 EUR
31.12.202320.2 B EUR85.16 EUR
Description

BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases. — Wikipedia

advertisement

Exchanges and tickers

ExchangeTickerCurrencyPriceType
common stock
XETRA Xetra22UA primaryEUR76.65 -1.60%common stock
LSE London Stock Exchange0A3M IOBUSD87.51 +0.00%common stock
US USA StocksBNTX secondaryUSD81.38 -2.26%common stock
depositary receipt
SA B3 Sao PauloB1NT34BRL27.66 -4.62%depositary receipt

Price

Hover / tap a day — open, close, high and low prices

Dividends

Ex-datePaymentAmount%TypeTicker
2022-06-02—1.9328 EUR1.3/1.3 %—XETRA:22UA

Top holders

HolderStakeSharesReport date
SAHIN UGUR MD (Chief Exe…≈15.59%39.43 M2026-09-30
FMR, LLC2.99%7.57 M2026-06-30
Primecap Management Comp…1.49%3.77 M2026-06-30
Dodge & Cox Inc.1.45%3.68 M2026-06-30
Fidelity Contrafund1.26%3.18 M2026-07-31
Dodge & Cox Funds-Dodge…1%2.52 M2026-06-30
Flossbach von Storch SE0.88%2.23 M2026-06-30
VANGUARD HORIZON FUNDS-V…0.87%2.19 M2026-06-30
T. Rowe Price Investment…0.82%2.07 M2026-06-30
Blackrock Inc.0.73%1.85 M2026-06-30
Temasek Holdings (Privat…0.6%1.51 M2026-06-30
BNP Paribas Financial Ma…0.52%1.32 M2026-06-30
T. Rowe Price Mid-Cap Gr…0.4%1.02 M2026-06-30
Logos Global Management…0.4%1.02 M2026-06-30
First TRT Exch-Trd Fd.-F…0.39%989 5802026-08-31
PRIMECAP Odyssey Funds-P…0.35%897 1562026-07-31
GSK plc0.35%889 8242026-06-30
iShares Trust-iShares Bi…0.27%683 7522026-08-31
Fidelity Contrafund-Fide…0.27%683 0652026-07-31
Fidelity Investment Trus…0.26%660 8002026-07-31
Dodge & Cox Funds-Dodge…0.21%525 7782026-06-30
AT Impf———
POETTING SIERK (Chief Op…——2026-04-22